Bioequivalence Study of AJU-R713 and R713R in Healthy Adult Volunteers

Exclusion Criteria

• •Use of drugs known to induce or inhibit drug-metabolizing enzymes within 30 days prior to the first dose, or any medication likely to interfere with the study within 10 days prior to dosing.
• •Participation in any clinical trial involving investigational products within 6 months prior to the first dose.
• •Whole blood donation within 8 weeks, or component blood donation within 2 weeks prior to the first dose.
• •History of gastrointestinal surgery that may affect drug absorption (excluding appendectomy and hernia repair).
• •Known hypersensitivity to the investigational product or its components.
• •Known metabolic or genetic disorders such as galactose intolerance, lactase deficiency, glucose-galactose malabsorption, or phenylketonuria.
• •History of clinically significant psychiatric illness.
• •Pregnant or breastfeeding women, or women with a possibility of pregnancy.